How many times in a year does withdrawal bleeding occur in extended continuous regimens of combined oral contraceptive pills?
Which of the following are examples of LARC (Long Acting Reversible Contraceptives) ? 1. Copper-T 380A 2. Implants 3. LNG-IUS Select the correct answer using the code given below :
Which of the following are correct regarding 'Chhaya' contraceptive ? 1. It has potent anti-estrogenic and weak estrogenic property. 2. Failure rate is 1 - 4 per HWY (Hundred Women Years) of use. 3. It inhibits ovulation. 4. It creates asynchrony between zygote and endometrium. Select the correct answer using the code given below :
Consider the following statements regarding LNG-20 (Mirena) : 1. It is a T-shaped IUD filled with natural hormone progesterone. 2. It is associated with a low pregnancy rate (2 per 1000 women). 3. It is associated with a large number of ectopic pregnancies. 4. It is associated with lower menstrual blood loss as compared to copper IUDs. Which of the statements given above is/are correct?
Which of the following conditions are indications of removal of intrauterine device? 1. Persistent irregular uterine bleeding 2. Perforation of uterus 3. Pyelonephritis 4. Pregnancy with device in situ Select the correct answer using the code given below.
Which of the following is a contraindication for insertion of Intrauterine Contraceptive Device (IUCD)?
Which of the following is not an absolute contraindication for insertion of intrauterine device (IUD) ?
Following which of the tubectomy procedures listed below, best result is achieved for reversal sterilization (recanalization procedure) ?
Following statements are correct about levonorgestrel containing intra-uterine contraceptive device (Mirena) except
Combined oral pills protect the woman against all except
Explanation: **4** - **Extended continuous regimens** of combined oral contraceptive pills typically involve taking active pills for 84 days, followed by a 7-day placebo or hormone-free interval. - This regimen results in **four withdrawal bleeds per year**, as opposed to thirteen for conventional cyclic regimens. *6* - This frequency of withdrawal bleeding would be more common with regimens that have shorter active pill cycles, such as 21 days active with 7 days off, but not with typical extended continuous use. - While some custom regimens might approach this frequency, it is not the standard for "extended continuous" which aims to reduce bleeding frequency. *3* - A frequency of three withdrawal bleeds per year would imply a longer continuous active pill phase than the typical 84 days, such as 112 days on active pills followed by a 7-day break. - While such regimens exist, they are less commonly described as the standard "extended continuous" which typically refers to the 84/7 day cycle. *5* - Five withdrawal bleeds per year is not a standard frequency for either conventional cyclic or typical extended continuous oral contraceptive regimens. - It would require an unusual cycle length for active pills and break days that does not correspond to common prescribing patterns.
Explanation: ***1, 2 and 3*** - **Long-acting reversible contraceptives (LARCs)** include all methods that are effective for an extended period, do not require daily attention, and are reversible. The **Copper-T 380A intra-uterine device (IUD)**, **subdermal implants**, and the **levonorgestrel-releasing intra-uterine system (LNG-IUS)** all fit this description. - These methods are highly effective due to minimal user error and provide contraception for several years, making them ideal for long-term birth control. *1 and 3 only* - This option incorrectly excludes **implants**, which are a well-established and highly effective form of LARC, offering contraception for up to three years. - While Copper-T 380A and LNG-IUS are indeed LARCs, the exclusion of implants makes this option incomplete. *1 and 2 only* - This option incorrectly excludes the **levonorgestrel-releasing intra-uterine system (LNG-IUS)**, which is an increasingly popular and effective LARC, providing contraception for up to five years. - The LNG-IUS is a hormonal LARC often used for both contraception and managing heavy menstrual bleeding. *2 and 3 only* - This option incorrectly excludes the **Copper-T 380A IUD**, which is a non-hormonal LARC. - The Copper-T 380A is one of the most widely used LARCs globally, offering highly effective contraception for up to ten years.
Explanation: ***1, 2 and 4*** - **Chhaya (Centchroman)** is a **non-steroidal oral contraceptive** that acts primarily through its **anti-estrogenic effects** on the endometrium, while also possessing weak estrogenic properties. - Its mechanism of action leads to **asynchrony between the zygote and endometrium**, preventing implantation, and it has a reported **failure rate of 1-4 per 100 women-years**. *1, 3 and 4* - This option incorrectly includes the statement that Chhaya **inhibits ovulation**. Chhaya is a **non-hormonal contraceptive** and does not primarily prevent ovulation; rather, it makes the uterus unreceptive to implantation. - Its main contraceptive effect is through altering the endometrium, which does not typically include an anovulatory mechanism. *2, 3 and 4* - This option is incorrect because Chhaya **does not inhibit ovulation**. This mechanism is typically associated with hormonal contraceptives, which suppress the hypothalamic-pituitary-ovarian axis. - The primary action of Chhaya is on the endometrium, making it unsuitable for implantation, not preventing the release of an egg. *1, 2 and 3* - This option is incorrect because Chhaya **does not inhibit ovulation**. While it has potent anti-estrogenic and weak estrogenic properties (1) and a failure rate of 1-4 per HWY (2), it does not act by preventing egg release (3). - Its contraceptive efficacy is mainly due to its impact on the endometrial lining and ovum transport.
Explanation: ***Correct Option: Statements 2 and 4*** - **Statement 2 is TRUE**: The Mirena IUD (LNG-20) is highly effective with a very **low pregnancy rate** (approximately 0.2% or 2 per 1000 women per year), making it one of the most reliable forms of contraception. This high efficacy is due to the continuous release of levonorgestrel, which thickens cervical mucus, thins the uterine lining, and inhibits sperm function. - **Statement 4 is TRUE**: Mirena is associated with **significantly reduced menstrual blood loss** compared to copper IUDs. In fact, many women experience amenorrhea (absence of periods) or very light bleeding, which is one of its therapeutic benefits. This makes it useful for treating menorrhagia (heavy menstrual bleeding). *Incorrect Statement 1* - The Mirena IUD contains **synthetic levonorgestrel** (a progestin), NOT natural progesterone. While it is T-shaped, the hormone component is incorrectly described in this statement. *Incorrect Statement 3* - Mirena is NOT associated with a large number of ectopic pregnancies. While there may be a slight increase in the *proportion* of pregnancies that are ectopic IF conception occurs with an IUD in place, the **overall absolute risk of ectopic pregnancy is significantly reduced** compared to women not using contraception. This is because the overall pregnancy rate is so low. *Option: 2, 3 and 4* - Incorrect because statement 3 is false. Mirena does not cause a large number of ectopic pregnancies. *Option: 1, 3 and 4* - Incorrect because both statements 1 and 3 are false. Statement 1 incorrectly identifies the hormone as natural progesterone (it's synthetic levonorgestrel), and statement 3 falsely claims a large number of ectopic pregnancies. *Option: 1 and 2* - Incorrect because statement 1 is false (contains levonorgestrel, not natural progesterone), and this option omits the true statement 4 about reduced menstrual blood loss.
Explanation: ***1, 2 and 4*** - **Persistent irregular uterine bleeding** that does not respond to medical management is an indication for IUD removal according to WHO guidelines and standard clinical practice. After ruling out other causes and attempting conservative management, persistent problematic bleeding warrants removal. - **Uterine perforation** by an IUD is a serious complication requiring immediate removal to prevent further injury, infection, migration of the device, or damage to adjacent organs. - **Pregnancy with an IUD in situ** increases the risk of complications including septic abortion, miscarriage, preterm birth, and chorioamnionitis. If the IUD strings are visible, removal is recommended (preferably in the first trimester). *1 and 2* - While these are both valid indications, this option is incomplete as it omits pregnancy with IUD in situ, which is also a strong indication for removal. *2 and 4* - Both uterine perforation and pregnancy with IUD are indications for removal, but this option incorrectly excludes persistent irregular uterine bleeding, which is also an indication when unresponsive to treatment. *1, 2 and 3* - **Pyelonephritis** (kidney infection) is not an indication for IUD removal as it is a urinary tract infection unrelated to IUD use. The IUD does not cause or complicate pyelonephritis, and treatment involves appropriate antibiotics without device removal.
Explanation: ***Suspected pregnancy*** - Insertion of an IUCD into a pregnant uterus is an **absolute contraindication** (WHO MEC Category 4). - Can lead to **septic abortion**, **miscarriage**, **uterine perforation**, or **ectopic pregnancy complications**. - **Pregnancy must be ruled out** before IUCD insertion through history, examination, and urine pregnancy test if indicated. *Age > 35 years* - Age alone is **not a contraindication** for IUCD insertion. - IUCDs are safe and highly effective for women over 35 years. - In fact, IUCDs are often preferred for older reproductive-age women due to high efficacy and non-hormonal options. *Severe dysmenorrhea* - **Not an absolute contraindication** for IUCD insertion. - **Copper IUCDs** may worsen dysmenorrhea and should be used with caution. - **Levonorgestrel-releasing IUCDs (LNG-IUS)** are actually **therapeutic** for severe dysmenorrhea and reduce menstrual blood loss. - The type of IUCD can be selected based on the clinical scenario. *Multiple sexual partners* - **Not a contraindication** for IUCD insertion per WHO Medical Eligibility Criteria. - While multiple partners increase STI risk, this can be addressed through **STI screening** and **barrier contraception counseling**. - IUCDs do not increase risk of PID in women without current cervical infection. - The outdated concern about PID risk has been refuted by modern evidence.
Explanation: ***Severe dysmenorrhea*** - While IUDs (especially copper IUDs) can exacerbate **dysmenorrhea** and **menorrhagia** in some women, it is not an absolute contraindication for insertion. Progestin-releasing IUDs can even improve dysmenorrhea. - The decision to insert an IUD in a patient with severe dysmenorrhea requires careful consideration of the **type of IUD** and potential benefits versus risks, but it is not an outright medical barrier. *Puerperal sepsis* - **Puerperal sepsis** indicates an active infection of the genital tract following childbirth. - Inserting an IUD into an infected uterus carries a high risk of worsening the infection, potentially leading to **septic shock** or **pelvic inflammatory disease (PID)**. *Pelvic tuberculosis* - **Pelvic tuberculosis** is a chronic inflammatory infection of the reproductive organs. - The presence of active pelvic tuberculosis makes the uterus and surrounding tissues highly susceptible to further infection or exacerbation of the existing disease with IUD insertion, leading to severe complications and **abscess formation**. *Endometrial cancer* - **Endometrial cancer** is a malignancy of the uterine lining. - Inserting an IUD into a uterus with cancer could potentially **disseminate cancer cells**, complicate treatment, or mask the progression of the disease.
Explanation: ***Fallopian ring occlusion*** - This method uses a **silicone band** to occlude the fallopian tube, causing minimal damage to the surrounding tissue. - The small segment of the tube affected allows for a **higher success rate** in re-anastomosis during reversal sterilization due to preserved tubal length and integrity. *Electrocoagulation* - This method involves **burning and destroying** a significant segment of the fallopian tube with an electric current. - The extensive tissue damage and scarring make **recanalization difficult** and significantly reduce the success of reversal. *Irving method* - This procedure involves **ligating and dissecting** the fallopian tube, then burying the proximal end into the broad ligament. - The complex anatomical alteration and potential for **significant scarring** make reversal challenging and less successful. *Pomeroy ligation* - This technique involves **ligating and excising a loop** of the fallopian tube, which causes moderate tissue damage and segment removal. - While reversal is possible, the **removal of a tubal segment** can result in a shorter tube and a lower success rate compared to tubal ring occlusion.
Explanation: ***It increases the risk of ectopic pregnancy*** - This statement is **INCORRECT**. The **levonorgestrel-releasing IUD (Mirena)** does NOT increase the absolute risk of ectopic pregnancy compared to women not using contraception. - In fact, it **significantly reduces** the risk of ectopic pregnancy by preventing pregnancy altogether. The absolute risk of ectopic pregnancy is much lower in IUD users than in non-contraceptive users. *It reduces the risk of pelvic inflammatory disease* - The **levonorgestrel-releasing IUD (Mirena)** actually reduces the risk of PID. This is because **progestin thickens cervical mucus**, creating a barrier that can prevent ascending infection. - Unlike older copper IUDs, newer IUDs (both copper and hormonal) are generally not associated with an increased risk of PID after the first month following insertion. *It releases 20 µg/day of levonorgestrel* - The **Mirena IUD** is designed to release approximately **20 micrograms of levonorgestrel per day** initially, which then gradually decreases over its lifespan. - This consistent low-dose release is crucial for its contraceptive and therapeutic effects. *It increases the risk of ovarian cyst formation* - **Levonorgestrel-releasing IUDs** can increase the incidence of **functional ovarian cysts**. This is because the hormonal action can interfere with the normal follicular development and ovulation cycle. - These cysts are usually benign, asymptomatic, and resolve spontaneously.
Explanation: ***Venous thromboembolism*** - Combined oral contraceptives (COCs) contain estrogen, which increases the synthesis of **coagulation factors**, elevating the risk of **venous thromboembolism (VTE)**. - While the absolute risk is low, it is a known serious side effect and COCs do not protect against it; rather, they can increase its likelihood. *Pelvic inflammatory disease* - **Combined oral pills** can reduce the risk of **pelvic inflammatory disease (PID)** by thickening cervical mucus, which acts as a barrier to ascending infections. - They also decrease menstrual flow and endometrial proliferation, making the uterus less hospitable to infection. *Benign breast disease* - Combined oral contraceptives have been shown to **reduce the incidence of benign breast diseases**, such as fibrocystic changes and fibroadenomas. - This protective effect is thought to be related to the hormonal regulation provided by the pills. *Menorrhagia* - COCs are commonly used to treat **menorrhagia (heavy menstrual bleeding)** as they regulate the menstrual cycle and reduce the amount and duration of bleeding. - The progestin component thins the endometrial lining, leading to lighter periods.
Natural Family Planning Methods
Practice Questions
Barrier Methods
Practice Questions
Hormonal Contraceptives
Practice Questions
Intrauterine Devices
Practice Questions
Emergency Contraception
Practice Questions
Permanent Contraception Methods
Practice Questions
Contraception in Special Populations
Practice Questions
Contraceptive Counseling
Practice Questions
Side Effects and Complications of Contraceptives
Practice Questions
Future Contraceptive Technologies
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free